Product image of Moksifloksacin Kabi (Moxifloxacin Hydrochloride) supplied by GNH India

Moksifloksacin Kabi

Active Ingredient:
Moxifloxacin Hydrochloride
Origin:
EU

Moksifloksacin Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin Hydrochloride, the active ingredient in Moksifloksacin Kabi, is a fluoroquinolone antibiotic presented as an injection for intravenous use. It treats a range of serious bacterial infections in adult patients.

GNH India supplies Moksifloksacin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Fresenius Kabi Deutschland Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Moksifloksacin Kabi is a fluoroquinolone used for severe bacterial infections affecting various organ systems.

  • Community‑Acquired Pneumonia: effective treatment of moderate to severe cases caused by susceptible pathogens.
  • Acute Bacterial Sinusitis: eradicates infection when oral therapy is insufficient.
  • Acute Exacerbation of Chronic Bronchitis: reduces bacterial load and improves respiratory function.
  • Skin and Soft Tissue Infections: combats Gram‑negative and Gram‑positive organisms.
  • Intra‑Abdominal Infections: provides broad‑spectrum coverage for mixed flora.
  • Complicated Urinary Tract Infections: treats infections caused by resistant strains.

How It Works

  • Moxifloxacin Hydrochloride inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and transcription. By binding to these targets, it prevents supercoiling and separation of DNA strands, leading to bacterial cell death and a bactericidal effect against a wide range of Gram‑negative and Gram‑positive organisms.

Side Effects

Moksifloksacin Kabi may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects

  • Nausea: mild gastrointestinal upset.
  • Diarrhea: loose stools, often self‑limiting.
  • Headache: transient cranial discomfort.
  • Elevated liver enzymes: mild hepatic enzyme rise.
  • Injection site pain: local discomfort after IV administration.
  • Rash: non‑specific skin eruption.

Serious or Rare Side Effects

  • Tendon rupture: especially in older patients or those on corticosteroids.
  • QT interval prolongation: may precipitate cardiac arrhythmias.
  • Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome.
  • Clostridioides difficile colitis: severe intestinal infection.
  • Hepatotoxicity: marked liver injury.
  • Peripheral neuropathy: sensory disturbances.

Precautions & Warnings

Before using Moksifloksacin Kabi, clinicians should consider several safety aspects.

  • Renal impairment: adjust therapy in patients with reduced kidney function.
  • Hepatic disease: monitor liver function tests during treatment.
  • Cardiac risk: avoid in patients with known QT prolongation or electrolyte disturbances.
  • Concomitant corticosteroids: increase vigilance for tendon disorders.
  • Pregnancy and lactation: use only if the potential benefit justifies the potential risk.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Moksifloksacin Kabi can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

  • Antacids containing aluminum or magnesium: reduce absorption of the drug.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of central nervous system stimulation.
  • Cyclosporine: may raise cyclosporine concentrations.

Moderate Interactions (Monitor Closely)

  • Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
  • Theophylline: possible increase in plasma levels, watch for toxicity.
  • Corticosteroids: heightened risk of tendon rupture, monitor musculoskeletal symptoms.

Frequently Asked Questions

Moksifloksacin Kabi contains moxifloxacin hydrochloride, a fluoroquinolone antibiotic administered intravenously to treat serious bacterial infections such as community‑acquired pneumonia, intra‑abdominal infections, and complicated urinary tract infections in adult patients.

Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By blocking these targets, it prevents bacterial cell division and leads to a bactericidal effect against a broad spectrum of Gram‑negative and Gram‑positive organisms.

The dosage and infusion rate of Moksifloksacin Kabi are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local antimicrobial guidelines.

Safety data for moxifloxacin in pregnancy and lactation are limited. It should be used only if the potential benefit outweighs the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Moxifloxacin offers a broader spectrum against Gram‑positive organisms and better activity in respiratory infections compared with older fluoroquinolones such as ciprofloxacin. It also has a more favorable dosing schedule for IV use, but safety considerations like QT prolongation remain similar across the class.

Moksifloksacin Kabi should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

The product is supplied as a sterile solution for intravenous infusion. It is administered by a healthcare professional through a controlled IV line, following aseptic technique and the infusion rate prescribed by the treating physician.

Serious risks include tendon rupture, QT interval prolongation leading to arrhythmias, severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, and potential hepatotoxicity. Prompt medical attention is required if any of these occur.

Patients with known hypersensitivity to moxifloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, individuals with significant QT prolongation, and patients receiving concomitant medications that strongly interact (e.g., certain antacids) should avoid this product unless a clinician determines it is essential.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Moxifloxacin Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT